Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02820935 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibition and Induction on the Pharmacokinetics of CC-220 in Healthy Subjects
A Phase 1 study, sponsored by Celgene Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT02820935 is a Phase 1 study that has completed, run by Celgene Corporation. The registered enrollment target is 36 participants.
The verdict
NCT02820935, a Phase 1 study, has completed, sponsored by Celgene Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
This is a two-part study to be conducted at a single study site in the US. Both parts of the study may be conducted in parallel. A total of approximately 38 subjects will participate in this study, with approximately 19 subjects in Part 1 and approximately 19 subjects in Part 2. Each subject may only participate in one of the parts.
Interventions
- DRUG Rifampin
- DRUG Itraconazole
- DRUG CC-220
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2016-07 |
| Est. Completion | 2016-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02820935
The ClinicalTrials.gov registry entry for NCT02820935 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene Corporation, which has 40 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Rifampin is the first listed.
NCT02820935 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02820935 about?
NCT02820935 is a clinical study titled "Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibition and Induction on the Pharmacokinetics of CC-220 in Healthy Subjects". This is a two-part study to be conducted at a single study site in the US. Both parts of the study may be conducted in parallel. A total of approximately 38 subjects will participate in this study, with approximately 19 subjects in Part 1 and approximately 19 subjects in Part 2. Each subject may on...
What is the current status of trial NCT02820935?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2016-07. Estimated completion is 2016-09.
What interventions are being tested in trial NCT02820935?
The interventions under investigation include: Rifampin (DRUG), Itraconazole (DRUG), CC-220 (DRUG).
Who is sponsoring clinical trial NCT02820935?
This trial is sponsored by Celgene Corporation, which has 40 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.